Compare Agilent Technologies Inc (A) vs Amylx Pharmaceuticals Inc (AMLX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Agilent Technologies Inc vs Amylx Pharmaceuticals Inc — how do they compare? Agilent Technologies Inc trades at $128.67 (market cap $37.04B), while Amylx Pharmaceuticals Inc trades at $17.85 (market cap $2.02B). The key difference: Agilent Technologies Inc is far larger — about 18.3× Amylx Pharmaceuticals Inc's market cap, and Agilent Technologies Inc pays a 0.78% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| A | AMLX | |
|---|---|---|
Market Cap | $37.04B | $2.02B |
Sector | Health | Health |
52-Week High | $157.20 | $18.70 |
52-Week Low | $110.24 | $6.98 |
Enterprise Value | $38.59B | $1.75B |
Dividend Yield | 0.78% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $131.14, up 0.34% on the day, with a bearish technical signal but strong analyst support. The stock shows solid profitability with a net margin of 19.55% and ROE of 21.33%, supported by recent earnings beats. Recent acquisitions like Biocare Medical highlight growth initiatives, while cash flow trends remain positive. Valuation ratios such as P/E of 26.22 are elevated but align with quality growth expectations.
The outlook is positive given analyst consensus with a $154.90 price target and 77.5% buy ratings. Risks include execution of acquisitions and macroeconomic pressures on life sciences spending. The stock offers growth potential from AI-driven product launches, though technical resistance near $132 may cap near-term gains.
AMLX trades at $17.97, down 1.64% today, with strong analyst support showing 91% buy ratings and a $30.50 consensus price target representing 70% upside potential. The stock shows bullish technical momentum with positive moving average signals, though RSI levels suggest some overbought conditions. Recent earnings showed mixed results with a Q1 2026 miss after two previous beats, while the company continues advancing its pipeline with Phase 3 data for avexitide expected in Q3 2026.
Despite negative profitability metrics and cash burn, AMLX maintains strong institutional confidence with 11 analysts covering the stock. The key catalyst remains the upcoming Phase 3 avexitide readout, though risks include ongoing class action litigation and the company's negative cash flow from operations. Current valuation at 7.31x book value reflects optimism around pipeline assets rather than current financial performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Agilent Technologies Inc
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →
